Stephen Liu on Muck Rack

Stephen Liu

West
As seen in: Markets Insider, Nature, MDPI, International Business Times (U.S.), Medscape, GlobeNewswire, KTLA-TV (Los Angeles, CA), Morningstar, KDVR-TV (Denver, CO), StreetInsider and
privycircle.com privycircle.eth privy.net privy.eth privy.sol privy/

Get in touch with Stephen

Contact Stephen, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Articles

SourceBench: Can AI Answers Reference Quality Web Sources?

|
By Stephen Liu, Yuheng Li, Simran Malik
| arxiv.org
arXivLabs is a framework that allows collaborators to develop and share new arXiv features directly on our website. Both individuals and organizations that work with arXivLabs have embraced and accepted our values of openness, community, excellence, and user data privacy. arXiv is committed to these values and only works with partners that adhere to them. Have an idea for a project that will add value for arXiv's community? Learn more about arXivLabs.
Open in Who Shared View Duplicates (472) Issue with article?

OnePiece: A Large-Scale Distributed Inference System with RDMA for Complex AI-Generated Content (AIGC) Workflows

|
By Stephen Liu, Neal Xu, Gragas Huang, Bok Zhou
| arxiv.org
arXivLabs is a framework that allows collaborators to develop and share new arXiv features directly on our website. Both individuals and organizations that work with arXivLabs have embraced and accepted our values of openness, community, excellence, and user data privacy. arXiv is committed to these values and only works with partners that adhere to them. Have an idea for a project that will add value for arXiv's community? Learn more about arXivLabs.
Open in Who Shared View Duplicates (392) Issue with article?

Expanding targeted therapy for lung cancer - Nature Cancer

|
By Stephen Liu
| Nature Verified
Targeted therapies continue to transform the landscape of non-small-cell lung cancer (NSCLC). In 2025, the US Food and Drug Administration approved two targeted therapies, an antibody–drug conjugate and a tyrosine kinase inhibitor, for specific molecular subtypes of NSCLC. In this Clinical Outlook, we discuss their impact on the field.
Open in Who Shared Issue with article?
See all 113 licensed articles (230 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified